SLU-PP-332 Dosage Guide: Protocols, Calculator & Safety

A defensible beginner protocol for SLU-PP-332 first addresses a practical question: given the compound's poor oral bioavailability, are you prepared to inject it? Every published rodent study used intraperitoneal injection, and self-experimenters have reported using subcutaneous or intramuscular routes with uncertain relationship to the rodent pharmacology data. If you want the rodent-equivalent effects, you need injection-based dosing, not oral. If you prefer oral dosing for convenience, SLU-PP-915 is the appropriate choice. Beginners who proceed with SLU-PP-332 need baseline assessment. Labs for a beginner SLU-PP-332 cycle: comprehensive metabolic panel (creatinine, eGFR, liver enzymes, electrolytes, glucose); CBC with differential; lipid panel including ApoB and Lp(a); fasting insulin and HbA1c; TSH, free T3, free T4; high-sensitivity CRP; testosterone/estradiol/SHBG for men, estradiol/FSH/LH/progesterone as appropriate for women. Baseline cardiovascular assessment for users over 35: resting ECG, resting blood pressure trending, consideration of coronary calcium score for users with risk factors. Baseline body composition: DEXA if available, otherwise scale weight, waist circumference, and photos. A conservative beginner SLU-PP-332 dose from self-report community reports is 3-5 mg per injection subcutaneously once daily or every other day. The dosing is empirically derived from rodent dose extrapolation using body surface area conversions that carry substantial uncertainty. Beginners should start at the low end (3 mg every other day) and hold at the starting dose for at least 2-3 weeks before any titration. Cycle duration for beginners is typically 4-6 weeks of injection-based dosing followed by a break of 4-8 weeks. Route of administration for self-experimenters is subcutaneous or intramuscular. Subcutaneous is the easier route using insulin syringes (28-31 gauge); IM administration requires longer needles (22-25 gauge, 1-1.5 inch) and appropriate anatomical sites (deltoid, ventrogluteal, vastus lateralis). The question of whether SC/IM SLU-PP-332 produces rodent-equivalent exposure is unanswered — IP administration in rodents bypasses first-pass metabolism and provides rapid systemic distribution, while SC/IM in humans may produce different PK. Timing of administration: morning dosing is typical. Monitoring during a beginner cycle should include subjective tracking of training performance (particularly endurance), body composition, sleep quality, gastrointestinal tolerance, and any unusual symptoms. Mid-cycle labs (week 3) and end-of-cycle labs (week 6) to check for changes in liver enzymes, renal function, glucose, lipids, thyroid markers. Post-break labs (4 weeks after stopping). Decision framework after one beginner cycle: if the cycle produced clearly adverse effects, stop; if the cycle produced no detectable effects after 6 weeks, reconsider; if coherent improvements emerged without adverse effects, cautious continuation. The beginner protocol specifically avoids stacking SLU-PP-332 with multiple other research chemicals in the first cycle — a clean first cycle alone provides actual information about what this compound does for you. Beginners should also consider whether SLU-PP-915 is a better fit given its oral bioavailability, as it provides most of the same mechanistic rationale without the injection burden.

Intermediate SLU-PP-332 users have completed at least one beginner cycle with documented baseline and post-cycle data, have experience with the injection requirement, and are considering longer or higher-dose protocols. An intermediate approach typically involves 5-10 mg per injection subcutaneously or intramuscularly once daily or twice daily for 6-10 week cycles with 4-6 week off-periods. The higher dose range is intended to extract larger effects on body composition, endurance, and metabolic markers. This assumption is empirically driven rather than clinically validated. Intermediate users often introduce stacking combinations. Common additions include 5-Amino-1MQ for complementary metabolic mechanism, L-Carnitine for substrate support, and GH secretagogues for lean mass support. More ambitious combinations may include Semaglutide or Tirzepatide for users pursuing weight loss. Each added compound introduces attribution loss. Intermediate users should consider whether their reasons for using SLU-PP-332 over SLU-PP-915 still hold. If the injection burden is acceptable and SLU-PP-332 is working for the user, continuation is reasonable. If injection is a limitation and SLU-PP-915 is available, migrating to the second-generation compound may be worth considering. Monitoring at the intermediate level expands on beginner monitoring. Quarterly labs: CMP, CBC, LFTs, lipid panel with ApoB and Lp(a), HbA1c and fasting insulin, hs-CRP, homocysteine, vitamin D, B12, folate, ferritin, thyroid panel, full hormone panel. Cardiovascular: daily BP trending, resting heart rate, repeat ECG, exercise stress testing if indicated. Body composition: DEXA at baseline, end of cycle, during off-cycle. Exercise performance: standardized endurance tests and resistance training performance tracking. Subjective tracking across all relevant domains. Cost at the intermediate stage. Research-chemical SLU-PP-332 typically costs $60-$200 per 25 mg vial. A 10-week cycle at 10 mg daily uses 700 mg of compound, costing $1,680-$5,600 per cycle. Two cycles annually runs $3,360-$11,200 just for SLU-PP-332. Adding stacked compounds, labs, and clinical consultations substantially increases annual cost. Users should evaluate cost-benefit relative to alternative health investments with validated ROI. Users who have cycled SLU-PP-332 at intermediate level without clear benefit should strongly consider discontinuing rather than escalating. The discipline of stopping when experiments don't work is an important protective factor. Clinical infrastructure at the intermediate stage should include a physician who understands research-chemical use, can order appropriate labs, and can evaluate any concerning findings. For users with significant cardiometabolic history, cardiology involvement is essential.

Advanced SLU-PP-332 protocols are used by experienced self-experimenters who have completed multiple intermediate cycles with documented positive response, have robust clinical monitoring, and are integrating SLU-PP-332 into comprehensive metabolic or body composition protocols. Advanced dosing can involve 10-20 mg per injection once or twice daily for 10-16 week cycles with 4-6 week off-periods. There is no published clinical evidence that higher doses produce proportionally better outcomes. The advanced question is integration within sophisticated metabolic and longevity stacks. A typical advanced cardiometabolic stack built around SLU-PP-332 might include: SLU-PP-332 at 10-15 mg daily SC; Semaglutide or Tirzepatide for GLP-1-based weight management; 5-Amino-1MQ for NNMT inhibition; L-Carnitine for fatty acid oxidation support; CoQ10 for electron transport chain support; NAD+/NR/NMN for NAD+ support; Methylene Blue for alternative electron bypass; CJC-1295 + Ipamorelin for GH/IGF-1 support; Humanin or MOTS-c for mitochondrial peptide support; validated medications as individually indicated. These stacks have no clinical validation for specific combinations. Attribution is impossible in complex stacks. Monitoring at the advanced level should be extensive — comprehensive quarterly labs, specialty testing every 6-12 months (biological age testing, inflammatory cytokine panels, oxidative stress markers), annual comprehensive imaging (coronary calcium score, carotid ultrasound, DEXA, echocardiogram), functional assessments (VO2max, grip strength, gait speed), and continuous wearable-based monitoring. Advanced users should develop clear decision criteria for protocol adjustment. Thresholds for stopping specific components, thresholds for adding new interventions, thresholds for escalating clinical involvement. Pre-committed criteria make rational decisions easier when ambiguous data arrive. Advanced users are in a position to contribute to the broader knowledge base through structured n=1 experiments with careful design. Advanced users should consider protocol exit and de-escalation — metabolic interventions do not need to be continued indefinitely. The overall theme of advanced SLU-PP-332 protocols is that sophistication can be escalated but the underlying evidence base remains limited to preclinical rodent data, attribution becomes impossible, cost and risk scale with complexity, and sophistication does not compensate for absence of clinical trial validation. Advanced users should also consider whether the injection burden of SLU-PP-332 compared to oral SLU-PP-915 still justifies use of the first-generation compound; for many advanced users, migrating to SLU-PP-915 for ERR pan-agonism coverage is reasonable.